Gastrointestinal medication burden among persons with the Ehlers-Danlos syndromes.
Ehlers-Danlos syndromes
gastrointestinal medications
prescription claims
visceral hypersensitivity drugs
Journal
Neurogastroenterology and motility
ISSN: 1365-2982
Titre abrégé: Neurogastroenterol Motil
Pays: England
ID NLM: 9432572
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
revised:
04
11
2020
received:
01
09
2020
accepted:
14
12
2020
pubmed:
5
1
2021
medline:
19
1
2022
entrez:
4
1
2021
Statut:
ppublish
Résumé
The Ehlers-Danlos syndromes (EDSs) are a group of heritable disorders of connective tissue associated with an increased prevalence of both structural and functional GI conditions. We used 10 years (2005-2014) of administrative claims data comprised of 4294 people with clinician-diagnosed EDS, aged 5-62 years, and compared their frequency of GI drug prescription claims to their age-, sex-, state of residence-, and earliest claim date-matched controls. We categorized the GI medications into the following groups: acid suppressants, anti-emetics, irritable bowel syndrome drugs, and visceral hypersensitivity (VHS) medications. Compared to controls, a significantly higher proportion of persons with EDS had prescription claims for at least one GI drug group, as well as for drugs in each of the four GI drug groups included in our study. By age-group, 25.7% children and 45.1% adults with EDS had prescription claims for at least one GI drug group compared with only 7.4% and 21.0% of controls, respectively (p < 0.0001). By gender, 44.0% of women and 25.3% of men with EDS had prescription claims for at least one class of GI drugs compared with 19.2% and 9.6% of controls, respectively (p < 0.0001). Predominant medication burden occurs among women with EDS, beginning peri-pubertally for anti-emetics and VHS drugs. High GI medication burden underscores previous evidence that GI dysmotility is common among persons with EDS.
Sections du résumé
BACKGROUND
The Ehlers-Danlos syndromes (EDSs) are a group of heritable disorders of connective tissue associated with an increased prevalence of both structural and functional GI conditions.
METHODS
We used 10 years (2005-2014) of administrative claims data comprised of 4294 people with clinician-diagnosed EDS, aged 5-62 years, and compared their frequency of GI drug prescription claims to their age-, sex-, state of residence-, and earliest claim date-matched controls. We categorized the GI medications into the following groups: acid suppressants, anti-emetics, irritable bowel syndrome drugs, and visceral hypersensitivity (VHS) medications.
KEY RESULTS
Compared to controls, a significantly higher proportion of persons with EDS had prescription claims for at least one GI drug group, as well as for drugs in each of the four GI drug groups included in our study. By age-group, 25.7% children and 45.1% adults with EDS had prescription claims for at least one GI drug group compared with only 7.4% and 21.0% of controls, respectively (p < 0.0001). By gender, 44.0% of women and 25.3% of men with EDS had prescription claims for at least one class of GI drugs compared with 19.2% and 9.6% of controls, respectively (p < 0.0001).
CONCLUSIONS AND KEY INFERENCES
Predominant medication burden occurs among women with EDS, beginning peri-pubertally for anti-emetics and VHS drugs. High GI medication burden underscores previous evidence that GI dysmotility is common among persons with EDS.
Substances chimiques
Gastrointestinal Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14077Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Blackburn PR, Xu Z, Tumelty KE, et al. Bi-allelic alterations in AEBP1 lead to defective collagen assembly and connective tissue structure resulting in a variant of Ehlers-Danlos syndrome. Am J Hum Genet. 2018;102(4):696-705.
Malfait F, Francomano C, Byers P, et al. The 2017 international classification of the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017;175(1):8-26.
Castori M. Ehlers-danlos syndrome, hypermobility type: an underdiagnosed hereditary connective tissue disorder with mucocutaneous, articular, and systemic manifestations. ISRN Dermatol. 2012;2012:751-768.
Beighton P, De Paepe A, Steinmann B, et al. Ehlers-Danlos syndromes: revised nosology, Villefranche, 1997. Ehlers-Danlos National Foundation (USA) and Ehlers-Danlos Support Group (UK). Am J Med Genet. 1998;77(1):31-37.
Almario CV, Ballal ML, Chey WD, et al. Burden of gastrointestinal symptoms in the United States: results of a nationally representative survey of over 71,000 Americans. Am J Gastroenterol. 2018;113(11):1701-1710.
Peery AF, Crockett SD, Murphy CC, et al. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2018 [published correction appears in Gastroenterology. 2019 May; 156(6):1936]. Gastroenterology. 2019;156(1):254-272.
Zhou Q, Verne GN. New insights into visceral hypersensitivity-clinical implications in IBS. Nat Rev Gastroenterol Hepatol. 2011;8(6):349-355.
Keszthelyi D, Troost FJ, Simren M, et al. Revisiting concepts of visceral nociception in irritable bowel syndrome. Eur J Pain. 2012;16:1444-1454.
Beckers AB, Keszthelyi D, Fikree A, et al. Gastrointestinal disorders in joint hypermobility syndrome/Ehlers-Danlos syndrome hypermobility type: a review for the gastroenterologist. Neurogastroenterol Motil. 2017;29(8):e13013. https://doi.org/10.1111/nmo.13013.
Camilleri M, Boeckxstaens G. Dietary and pharmacological treatment of abdominal pain in IBS. Gut. 2017;66(5):966-974.
Omori H, Hatamochi A, Koike M, et al. Sigmoid colon perforation induced by the vascular type of Ehlers-Danlos syndrome: report of a case. Surg Today. 2011;41(5):733-736.
Yoneda A, Okada K, Okubo H, et al. Spontaneous colon perforations associated with a vascular type of ehlers-danlos syndrome. Case Rep Gastroenterol. 2014;8(2):175-181.
Rothkopf M. Essential fatty acid deficiency (EFAD) in a patient with vascular Ehlers Danlos syndrome (EDS-4) (P12-053-19). Curr Dev Nutr. 2019;3(Suppl. 1):nzz035.P12-053-19.
Zeitoun JD, Lefevre JH, de Parades V, et al. Functional digestive symptoms and quality of life in patients with Ehlers-Danlos syndromes: results of a national cohort study on 134 patients. PLoS One. 2013;8:e80321.
Nelson AD, Mouchli MA, Valentin N, et al. Ehlers Danlos syndrome and gastrointestinal manifestations: a 20-year experience at Mayo Clinic. Neurogastroenterol Motil. 2015;27(11):1657-1666.
Manning J, Korda A, Benness C, et al. The association of obstructive defecation, lower urinary tract dysfunction and the benign joint hypermobility syndrome: a case-control study. Int Urogynecol J Pelvic Floor Dysfunct. 2003;14(2):128-132.
Fikree A, Aktar R, Grahame R, et al. Functional gastrointestinal disorders are associated with the joint hypermobility syndrome in secondary care: a case-control study. Neurogastroenterol Motil. 2015;27(4):569-579.
Fikree A, Chelimsky G, Collins H, et al. Gastrointestinal involvement in the Ehlers-Danlos syndromes. Am J Med Genet Part C Semin Med Genet. 2017;175C:181-187.
TruvenHealth. Marketscan databases and online tools. 2017. http://truvenhealth.com/your-healthcare-focus/life-sciences/data-databases-and-online-tools. Accessed July 12, 2020.
Heraty K. Examining differences in symptoms in individuals with hypermobile Ehlers-Danlos syndrome in relation to puberty. 2014. (Electronic Thesis or Dissertation). https://etd.ohiolink.edu/. Accessed July 12, 2020.
Tinkle B, Castori M, Berglund B, et al. Hypermobile Ehlers-Danlos syndrome (a.k.a. Ehlers-Danlos syndrome Type III and Ehlers-Danlos syndrome hypermobility type): clinical description and natural history. Am J Med Genet C Semin Med Genet. 2017;175(1):48-69.
Bergstralh EJ, Kosanke JL. Computerized Matching of Cases to Controls. Technical Report #56. Rochester, MN: Department of Health Sciences Research, Mayo Clinic; 1995.
SAS Software. Version 9.4. Cary, NC: SAS Institute Inc; 2014.
Hakim AJ, Grahame R. Non-musculoskeletal symptoms in joint hypermobility syndrome. Indirect evidence for autonomic dysfunction? Rheumatology (Oxford). 2004;43(9):1194-1195.
Castori M, Camerota F, Celletti C, et al. Natural history and manifestations of the hypermobility type Ehlers-Danlos syndrome: a pilot study on 21 patients. Am J Med Genet A. 2010;152A(3):556-564.
Lam CY, Palsson OS, Whitehead WE, et al. Rome IV functional gastrointestinal disorders and health impairment in subjects with hypermobility spectrum disorders or hypermobile Ehlers-Danlos syndrome [published online ahead of print, 2020 Feb 25]. Clin Gastroenterol Hepatol. 2020;S1542-3565(20)30204-4.
Nee J, Kilaru S, Kelley J, et al. Prevalence of functional gi diseases and pelvic floor symptoms in Marfan syndrome and Ehlers-Danlos syndrome: a national cohort study. J Clin Gastroenterol. 2019;53(9):653-659.
Alomari M, Hitawala A, Chadalavada P, et al. Prevalence and predictors of gastrointestinal dysmotility in patients with hypermobile Ehlers-Danlos syndrome: a tertiary care center experience. Cureus. 2020;12(4):e7881.
Heitkemper MM, Chang L. Do fluctuations in ovarian hormones affect gastrointestinal symptoms in women with irritable bowel syndrome? Gend Med. 2009;6(Suppl. 2):152-167.
de Kort LM, Verhulst JA, Engelbert RH, et al. Lower urinary tract dysfunction in children with generalized hypermobility of joints. J Urol. 2003;170(5):1971-1974.
Adib N, Davies K, Grahame R, et al. Joint hypermobility syndrome in childhood. A not so benign multisystem disorder? Rheumatology (Oxford). 2005;44(6):744-750.
Reilly DJ, Chase JW, Hutson JM, et al. Connective tissue disorder-a new subgroup of boys with slow transit constipation? J Pediatr Surg. 2008;43(6):1111-1114.
Vounotrypidis P, Efremidou E, Zezos P, et al. Prevalence of joint hypermobility and patterns of articular manifestations in patients with inflammatory bowel disease. Gastroenterol Res Pract. 2009;2009:924138.
Chey WD, Lembo AJ, Rosenbaum DP. Efficacy of tenapanor in treating patients with irritable bowel syndrome with constipation: a 12-week, placebo-controlled phase 3 trial (T3MPO-1). Am J Gastroenterol. 2020;115(2):281-293.
Quigley EM. Prucalopride: safety, efficacy and potential applications. Therap Adv Gastroenterol. 2012;5(1):23-30.
Kamuda JA, Mazzola N. Plecanatide (Trulance) for chronic idiopathic constipation and irritable bowel syndrome with constipation. P T. 2018;43(4):207-232.
Lembo AJ, Lacy BE, Zuckerman MJ, et al. Eluxadoline for irritable bowel syndrome with diarrhea. N Engl J Med. 2016;374(3):242-253.
Rao S, Lembo AJ, Shiff SJ, et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol. 2012;107(11):1714-1725.
Schubart JR, Schilling A, Schaefer E, et al. Use of prescription opioid and other drugs among a cohort of persons with Ehlers-Danlos syndrome: a retrospective study. Am J Med Genet Part A. 2019;179A:397-403.
Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain. 2010;150(3):573-581.
Oduyebo I, Camilleri M. Bile acid disease: the emerging epidemic. Curr Opin Gastroenterol. 2017;33(3):189-195.
Seneviratne SL, Maitland A, Afrin L. Mast cell disorders in Ehlers-Danlos syndrome. Am J Med Genet C Semin Med Genet. 2017;175(1):226-236.
Rombaut L, Malfait F, De Wandele I, et al. Medication, surgery, and physiotherapy among patients with the hypermobility type of Ehlers-Danlos syndrome. Arch Phys Med Rehabil. 2011;92(7):1106-1112.
Murray B, Yashar BM, Uhlmann WR, et al. Ehlers-Danlos syndrome, hypermobility type: A characterization of the patients’ lived experience. Am J Med Genet A. 2013;161A(12):2981-2988.
Castori M, Voermans NC. Neurological manifestations of Ehlers-Danlos syndrome(s): a review. Iran J Neurol. 2014;13(4):190-208.
Ericson WB Jr, Wolman R. Orthopaedic management of the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017;175(1):188-194.
Chopra P, Tinkle B, Hamonet C, et al. Pain management in the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017;175(1):212-219.
Henderson FC Sr, Austin C, Benzel E, et al. Neurological and spinal manifestations of the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017;175(1):195-211.
Gazit Y, Nahir AM, Grahame R, et al. Dysautonomia in the joint hypermobility syndrome. Am J Med. 2003;115(1):33-40.
Mathias CJ, Low DA, Iodice V, et al. Postural tachycardia syndrome-current experience and concepts. Nat Rev Neurol. 2011;8(1):22-34.
Hakim A, O'Callaghan C, De Wandele I, et al. Cardiovascular autonomic dysfunction in Ehlers-Danlos syndrome-Hypermobile type. Am J Med Genet Part C Semin Med Genet. 2017;175C:168-174.
Zarate N, Farmer AD, Grahame R, et al. Unexplained gastrointestinal symptoms and joint hypermobility: is connective tissue the missing link? Neurogastroenterol Motil. 2010;22(3):252-e78.
Fikree A, Grahame R, Aktar R, et al. A prospective evaluation of undiagnosed joint hypermobility syndrome in patients with gastrointestinal symptoms. Clin Gastroenterol Hepatol. 2014;12(10):1680-87.
Kovacic K, Chelimsky TC, Sood MR, Simpson P, Nugent M, Chelimsky G. Joint hypermobility: a common association with complex functional gastrointestinal disorders. J Pediatr. 2014;165(5):973-978.